Teens ages 14-17 with BMI in the 85th percentile or above and without diabetes are invited to participate in the HEALTHY BITES Research Study. The purpose of this research study is to find out if we can develop a mobile health approach that can improve diet quality in teens.

The purpose of this study is to find out if a video-guided hypnotherapy (VGH) program will improve the symptoms of those with a functional abdominal pain disorder (FAPD). This program uses guided relaxation, intense concentration, and focused attention to achieve a heightened state of awareness. These techniques can be used to help some people change certain behaviors, and it is also used to treat chronic pain. VGH does not feature direct in-person interaction with a psychotherapist (mental health professional), but rather recorded sessions that can be viewed at any time at the discretion of the patient. This study will use the video-guided hypnotherapy program that has been developed by Jeffrey Lazarus, MD, FAAP. Dr. Lazarus is a general pediatrician with an extensive background in the use of clinical hypnosis in children. He has been certified as an Approved Consultant by the American Society of Clinical Hypnosis.

Kids with IBD (inflammatory bowel disease) often struggle with tiredness and difficulty doing everyday activities, which can make life harder, but there aren't good tools to measure these problems in children. This study aims to create special tools to measure fatigue and disability in kids aged 2-18. Researchers will talk to kids and their parents to find out what issues matter most and use this information, along with medical records, to design the tools. The goal is to help doctors track these problems better and improve care for children with IBD. This study is being done in collaboration with the Shaare Zedek Medical Center. Participants will be compensated for their time and effort, upon completion of the interview.

The purpose of this research study is to help us understand how well tofacitinib works as a treatment for ulcerative colitis or indeterminate colitis in pediatric patients. We are looking to enroll, males or females ages 6 to 21 years old with a diagnosis of ulcerative colitis or indeterminate colitis who have started tofacitinib therapy prescribed by their primary gastroenterologist within the past 2 weeks or will be starting tofafacitinib within 1 month.